You are here

OrbiMed

Neurology-focused Brenig Therapeutics raises $65M in series A financing

FinSMEs

Tue, 07/23/24 - 11:27 am

Brenig Therapeutics

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

BioPharma Dive

Tue, 10/24/23 - 09:59 am

Rampart Biosciences

Alexion Pharmaceuticals

hypophosphatasia

Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

Fierce Biotech

Wed, 06/29/22 - 10:51 am

venture capital

autoimmune disease

Fueled by $111 Million, Sionna Therapeutics Takes Aim at Cystic Fibrosis

BioSpace

Tue, 04/19/22 - 11:48 pm

Sionna Therapeutics

cystic fibrosis

Vertex Pharmaceuticals

New OrbiMed-backed biotech aims to replicate Vertex's wildly successful cystic fibrosis pills in other diseases

Endpoints

Tue, 02/8/22 - 10:10 am

Congruence Therapeutics

Vertex Pharmaceuticals

protein misfolding

cystic fibrosis

OrbiMed takes point on a new biotech launch, but almost everything remains secret for now

Endpoints

Thu, 01/20/22 - 10:49 am

Alterome Therapeutics

OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO

Endpoints

Thu, 10/7/21 - 11:13 am

Theseus Pharmaceuticals

Spurred on by OrbiMed partner's diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers

Endpoints

Tue, 09/14/21 - 10:53 am

neurodegenerative disease

Five VC Firms Repeatedly Flex Financial Muscles in Biopharma

BioSpace

Thu, 05/27/21 - 10:59 am

Arch Venture Partners

Flagship Pioneering

venture capital

An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up

Endpoints

Tue, 05/18/21 - 10:55 am

corticosteroids

Sparrow Pharmaceuticals

OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance

MedCity News

Sun, 04/18/21 - 11:38 pm

Ariad Pharmaceuticals

Theseus Pharmaceuticals

Flush with $165M IPO cash, Zentalis entices Tybourne, OrbiMed to fund a $20M China joint venture

Endpoints

Wed, 05/20/20 - 10:48 am

Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world

Endpoints

Thu, 03/26/20 - 10:31 am

ReCode Therapeutics

cystic fibrosis

Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M

Endpoints

Tue, 07/30/19 - 11:27 am

Perceptive Advisors

Modis raises $30M series A for mitochondrial disorders

BioCentury

Mon, 10/1/18 - 07:18 pm

Aceras Life Sciences

mitochondrial disorders

The #MeToo Era Finally Catches Up to OrbiMed

Medical Devices and Diagnostics Industry

Tue, 05/1/18 - 09:57 am

sexual harassment

Report: OrbiMed founder Sam Islay harassed women for years, according to former employees

Mass Device

Wed, 12/6/17 - 11:05 am

sexual harassment

OrbiMed lines up $551M gamble on China, India biotech sectors

Endpoints

Tue, 09/5/17 - 11:03 am

venture capital

Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D

Fierce Biotech

Sun, 08/16/15 - 10:30 am

Rhythm Pharmaceuticals

Prader-Willi Syndrome